Fresenius Kabi

Germany - Bad HomburgBiotechnology2 H-1B visas (FY2023)

Focus: Fresenius Kabi is a German-headquartered specialty pharma company (5,000+ employees) focused on infusion therapy and injectable pharmaceuticals across oncology, infectious diseases, immunology, nephrology, and neurology.

Oncology Infectious Diseases Immunology Nephrology

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Employees

5000+

Open Jobs

132+1096 this month

Hot — 1184 jobs added in 30d

Net +1096 (1184 new, 88 removed). Aggressive expansion phase.

Should You Work at Fresenius Kabi?

AI assessment

Fresenius Kabi offers stable specialty pharma employment with strong cash products but carries near-term manufacturing credibility risk and long-term portfolio cliff exposure; best suited for operations, regulatory, and commercial roles rather than R&D.

Why Work Here

Strong portfolio anchored by VELPHORO ($466M Part D spend) and MAVENCLAD ($156M) generating near-term cash flow stability through 2035–2041 LOE dates.

Data completeness

6/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

NAROPIN

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

VELPHORO

Phosphate chelation (nephrology)

$466M

Peak8.6yr

Core revenue driver (72% of total); small-molecule NDA with 9-year runway; phosphate binder in chronic kidney disease, stable demand.

Help build intelligence for Fresenius Kabi

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

German multinational scale (5,000+ employees) with active hiring across manufacturing (27 roles), engineering (16), and commercial (14)—suggests growth investment despite portfolio concentration.

Specialist focus in nephrology, oncology, and immunology positions you in high-value therapeutic domains with fewer generics erosion than commodity injectables.

Watch Out For

Extreme revenue concentration (72% from single product VELPHORO) creates cliff risk and restructuring vulnerability when LOE approaches 2035; limited new molecular entities in pipeline to offset.
Recent FDA warning letters (Oct 2026) over sterile injectable contamination and active drug shortages (Carboplatin, Ketorolac, Propranolol) signal manufacturing / quality control stress that could trigger layoffs or division restructuring.
Pipeline is sparse in Phase 3 programs (only 2 active Phase 3 trials) and skewed toward observational studies and nutrition/parenteral therapy rather than novel drug candidates—limited career trajectory in R&D innovation.

Generated by Claude from Fresenius Kabi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MAVENCLAD

Lymphocyte depletion (neurology/immunology)

$156M

Peak14.8yr

Second-largest revenue source; oral NDA for multiple sclerosis / autoimmune indication; LOE extends to 2041, providing extended monetization window.

ANASTROZOLE

Advanced breast cancer (postmenopausal)

$16M

Post-LOE

ANDA generic; post-LOE status indicates commoditized aromatase inhibitor with limited differentiation; declining revenue trend.

PROGESTERONE

Secondary amenorrhea

$4M

Post-LOE

ANDA generic; minimal revenue; post-LOE lifecycle reflects mature generic market with margin pressure.

DAPTOMYCIN

cSSSI, endocarditis, pneumonia (infectious diseases)

$3M

Post-LOE

ANDA generic injectable antibiotic; post-LOE with minimal revenue; subject to active shortage reporting (limited availability).

SPRIX

Analgesia (pain management)

$2M

LOE_APPROACHING

NDA NSAID nasal spray approaching LOE; minimal revenue; subject to active shortages (unavailable/limited availability status).

CASPOFUNGIN ACETATE

Fungal infections (infectious diseases)

$819K

Peak6.1yr

NDA antifungal with LOE extending to 2032; minimal Part D spend; niche indication in hospital/ICU settings.

AUVI-Q

Anaphylaxis (emergency)

$719K

Peak11.1yr

NDA auto-injector with LOE to 2037; minimal revenue; specialty emergency care device-drug combination.

CHORIONIC GONADOTROPIN

Reproductive/hormone therapy

$565K

LOE_APPROACHING

BLA biologic hormone; minimal revenue; LOE approaching with no major clinical development signals.

PHOSLYRA

Phosphate binder (nephrology)

$388K

Peak3.3yr

NDA small-molecule phosphate binder; LOE 2030; minimal revenue; therapeutic category overlap with flagship VELPHORO creates internal competition.

Pipeline & Clinical Trials

Low protein diet with Fresubin® renal

Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT05330663Low Protein Renal Formula as Meal Replacement in Predialysis CKD Patients

N/A

Total Parenteral Nutrition with Glutamine

Moderate to Severe Trauma, as Defined by an

N/A

Clinical Trials (1)

NCT01250080Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.

N/A

Observational study: Supplemented protein-restricted diet

Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT02649205Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet

N/A

Observational study: Supplemented protein-restricted diet

Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT02756520Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)

N/A

Experimental group

Acute Myeloid Leukemia, Adult

N/A

Clinical Trials (1)

NCT04240600Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay

N/A

Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy

Arthroscopy

N/A

Clinical Trials (1)

NCT02184702Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy

N/A

Diben 1.5 kcal HP

Aneurysmal Subarachnoid Hemorrhage

N/A

Clinical Trials (1)

NCT02503527Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

N/A

Lactulose crystals 10 g

Blood Glucose

N/A

Clinical Trials (1)

NCT02968498Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers

N/A

Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery

Diabetes Mellitus, Type 1

N/A

Oral nutritional supplement, food for special medical purposes

Diabetes

N/A

Clinical Trials (1)

NCT01241695Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients

N/A

Combined cycle ergometry and bolus amino acid supplementation

Critical Illness

N/A

Clinical Trials (1)

NCT04099108Effect of Combined IV Bolus Amino Acid Supplementation and Mobilisation on Skeletal Muscle During the First 10 Days in the ICU: A RCT

N/A

Supportan

Enteral Nutrition

N/A

Clinical Trials (1)

NCT01025167The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients

N/A

Fresubin® Protein Energy DRINK

Hemodialysis Complication

N/A

Clinical Trials (1)

NCT05333692Oral Nutritional Supplementation of Hemodialysis Patients

N/A

Fresubin® powder fibre

Malnutrition

N/A

Clinical Trials (1)

NCT04474886Oral Nutritional Supplement for the Patient With or at Risk of Malnutrition

N/A

ProvideXtra DRINK

Enteral Nutrition

N/A

Clinical Trials (1)

NCT00600678Gastric Emptying Study After Administration of a High Caloric Sip Feed

N/A

Renalive® LP, flavour Vanilla

CKD

N/A

Clinical Trials (1)

NCT06892249Suitability of a High-energy, Low-protein Formula (Renalive® LP)

N/A

oral nutrition supplement, food for special medical purposes

Cachexia

N/A

Clinical Trials (1)

NCT00852020Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

N/A

sucrosomial iron

Iron-deficiency

N/A

Clinical Trials (1)

NCT04250298Sucrosom5al Iron Supplementation in Blood Donors

N/A

QoL and developed questionnaires for healthcare research

Tumors and Home Parenteral Nutrition

N/A

Clinical Trials (1)

NCT03425435Quality of Care of Oncological Patients With HPN

N/A

nutritional support program

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT02626195Preoperative Nutritional Support in Malnutritional Cancer Patients

N/A

International Nutrition Audit in FORegut TuMors

Head and Neck Cancer

N/A

Clinical Trials (1)

NCT02829489International Nutrition Audit in FORegut TuMors

N/A

Real World Use of Tocilizumab Biosimilar studY

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT06247722Real World Use of Tocilizumab Biosimilar studY

N/A

Rational Fluid Therapy in Germany

Patients in ICU

N/A

Clinical Trials (1)

NCT01122277Rational Fluid Therapy in Germany

N/A

Chronic Kidney Disease Observational Database - Taiwan

Chronic Kidney Insufficiency

N/A

Clinical Trials (1)

NCT03619564Chronic Kidney Disease Observational Database - Taiwan

N/A

preOP booster

Enteral Nutrition (Food for Special Medical Purposes)

N/A

Clinical Trials (1)

NCT00503334Preoperative Oral Nutritional Supplement (preOP Booster) in Visceral Surgery

N/A

oral nutritional supplement, food for special medical purposes

Cachexia

N/A

Clinical Trials (1)

NCT00851448Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients

N/A

Supplemental Parenteral Nutrition

Parenteral Nutrition

N/A

Clinical Trials (1)

NCT06510348Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction

N/A

High caloric, high protein ONS

Malnutrition

N/A

Clinical Trials (1)

NCT02938234Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake

N/A

Non-milked derived protein source formula diet

Acute Renal Failure

N/A

Clinical Trials (1)

NCT03715868Pre-operative Short-term Administration of a Formula Diet Containing a Non-milk-derived Protein Source for Prevention of Acute Kidney Injury After Cardiac Surgery

N/A

Swallow therapy in combination with individual dietary counselling

Neoplasms, Head and Neck

N/A

Clinical Trials (1)

NCT01110980Normalcy of Food Intake in Head and Neck Cancer Patients

N/A

Supportan® Drink, flavour Tropical Fruits

Cancer

N/A

Clinical Trials (1)

NCT06902402Evaluation of Safety and Efficacy of Supportan® Drink

N/A

PreOP Booster

Rectal Tumors

N/A

Clinical Trials (1)

NCT00730808Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery

N/A

Dietary Supplement: additional substitution of protein

ICU Acquired Weakness

N/A

Clinical Trials (1)

NCT05919940Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )

N/A

ONS

Healthy Participants

N/A

Clinical Trials (1)

NCT07479251Glycaemic Index Measurement of an Oral Nutritional Supplement With Biomarker Assessment and Lifestyle Monitoring in Healthy Participants

N/A

Fresubin Plant-based drink vanilla©

Risk of Malnutrition

N/A

Clinical Trials (1)

NCT07399886Plant-based Versus Animal-based Oral Nutritional Supplements

N/A

Nutrition Emulsion

Gastrointestinal Cancer

N/A

Clinical Trials (1)

NCT05606848To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

N/A

low protein diet + ketosteril

Acute Kidney Injury

N/A

Clinical Trials (1)

NCT02831062Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease

N/A

Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients

Surgery

N/A

Three-Chamber Bags Retrospective Study in Spain

Parenteral Nutrition

N/A

Clinical Trials (1)

NCT03284398Three-Chamber Bags Retrospective Study in Spain

N/A

α-Keto Acid with restricted protein diet

Renal Function Disorder

N/A

Clinical Trials (1)

NCT01255020Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients

N/A

Randomised 20g Protein Supplement

Healthy Male Volunteers Over 65

N/A

Clinical Trials (1)

NCT07038655Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique

N/A

SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimuma

Crohn Disease

N/A

Clinical Trials (1)

NCT05598684SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

N/A

The German Patient Blood Management Network

Clinical Safety of a PBM Program

N/A

calorie restriction

Acute Renal Failure

N/A

Clinical Trials (1)

NCT01534364Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery

N/A

PreOP Booster

Enteral Nutrition Regimen Prior to Surgery

N/A

Clinical Trials (1)

NCT00662376Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery

N/A

Observational study: Supplemented protein-restricted diet

Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT02746133Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-027-CNI)

N/A

High caloric, high protein ONS

Malnutrition

N/A

Clinical Trials (1)

NCT02938247Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake

N/A

Nutrition Insights Day Asia

Nutritional Status

N/A

Clinical Trials (1)

NCT03606603Nutrition Insights Day Asia

N/A

Screening Day Latin America

Nutritional Status

N/A

Clinical Trials (1)

NCT02583880Screening Day Latin America

N/A

Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critica

Critical Illness

N/A

Clinical Trials (1)

NCT04143503Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients

N/A

Interview Prep Quick Facts

Founded: 1999

Portfolio: 590 approved products, 109 clinical trials

Top TAs: Oncology, Infectious Diseases, Cardiovascular

H-1B (2023): 2 approvals

Publications: 33 in PubMed

Open Roles: 132 active jobs

Portfolio Health

Pre-Launch17 (3%)

Launch4 (1%)

Growth4 (1%)

Peak36 (6%)

LOE Approaching64 (11%)

Post-LOE465

Therapeutic Area Focus

Oncology

154 marketed16 pipeline

Infectious Diseases

59 marketed3 pipeline

Cardiovascular

48 marketed2 pipeline

Neurology

38 marketed

Nephrology

Hiring Trend

Actively Hiring

132

Open Roles

+202

Added

-7

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

12 active drug shortages

FDA warning letters (Oct 2026) over sterile injectable contamination + 12 active drug shortages (including flagship Ketorolac, Propranolol, Carboplatin) represent acute operational credibility crisis; expect regulatory remediation costs and potential manufacturing plant downtime/restructuring.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Conformational determinants of glucagon stability and aggregation kinetics in aqueous and commercial formulations.

Protein science : a publication of the Protein Society

2026

PMID:42557738

Strengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia.

ORAL, RECTAL · SOLUTION

20 marketed16 pipeline

Respiratory

26 marketed2 pipeline

Immunology

20 marketed8 pipeline

Hematology

23 marketed

Drug safety

2026

PMID:41863709

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Fresenius Kabi

Should You Work at Fresenius Kabi?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (184)

Key Products by Revenue

Other Products (173)

Pipeline & Clinical Trials

Recent News · Fresenius Kabi(10)

Open Jobs (132)

Validation Engineer

Compliance Officer

Electrical Controls Engineer

Sr. Manager Quality Assurance

Compliance Officer

Director, Deployment (SAP S/4HANA)

PACKAGING OPERATOR I

Sr Principal Engineer

PROJECT ENGINEER MANAGER

Principal Cybersecurity Engineer

Plasma Services Consultant (Oklahoma City/Tulsa)

ASSOCIATE PROJECT MANAGER

Sr. Technical Writer

SR. SCIENTIST

Sr Quality Engineer, Critical Systems

SR. TECHNICAL WRITER

Supervisor, Production (12-Hour Overnight Shift)

Aseptic Trainer

SUPERVISOR, MICROBIOLOGY

Lab Technician III

Supervisor, Production (12-Hour Day Shift)

Sr Manager, Sales Force Effectiveness (SFE)

Manager, Engineering (Automation)

Business Data Analyst

Filling Machine Operator - 4th Shift

Hiring Trend

Visa Sponsorship

Risk Signals

Research Publications(10)